Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer

142

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer

Tags:

Previous Article

Defining microglial-synapse interactions

Clinical sequelae of gut microbiome development and disruption in hospitalized p...

Related Posts

RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity

RBM39 degrader invigorates innate immunity to eradicate...

73

Global reorganization of genome architecture at the transition to gametogenesis

Global reorganization of genome architecture at the tra...

76

Next-generation immune profiling – beyond blood cancer cells

Next-generation immune profiling – beyond blood cancer ...

589